Agostinetto, Elisa
Eiger, Daniel
Punie, Kevin
de Azambuja, Evandro http://orcid.org/0000-0001-9501-4509
Article History
Accepted: 12 February 2021
First Online: 24 March 2021
Declarations
:
: Elisa Agostinetto has no potential conflicts of interest.Daniel Eiger: funding for his ESMO Fellowship (2018-2019) from Novartis. Speaker honoraria from Janssen.Kevin Punie: Honoraria for advisory/consultancy roles for AstraZeneca, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Hoffmann/La Roche, Teva and Vifor Pharma (paid to institution); speaker fees for Eli Lilly, Mundi Pharma, Novartis, Pfizer and Hoffmann/La Roche (paid to institution); research funding from Pfizer and Sanofi (paid to institution); travel support from AstraZeneca, Novartis, Pfizer, PharmaMar and Hoffmann/La Roche.Evandro de Azambuja: Honoraria and advisory board from Roche/GNE, Novartis, Seattle Genetics and Zodiacs; Travel grants from Roche/GNE and GSK/Novartis; Research grant to my institution from Roche/GNE, AstraZeneca, GSK/Novartis, and Servier.
: This article does not contain any studies with human or animal subjects performed by any of the author.